Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-101 + zidovudine is a combination of two small molecules: - **AS-101** is an organotellurium compound with immunomodulatory, anti-inflammatory, antiviral, and antimicrobial activity. It has been explored in the treatment of autoimmune diseases, inflammatory conditions, and for its antimicrobial effect against drug-resistant bacteria such as carbapenem-resistant Klebsiella pneumoniae (CRKP). - **Zidovudine** (also known as azidothymidine, AZT, or ZDV) is a nucleoside reverse transcriptase inhibitor (NRTI) primarily used for the treatment of HIV infection, but it also exhibits some broad-spectrum antiviral and antimicrobial effects. Recent research demonstrates that the combination of AS-101 and zidovudine exhibits strong *synergistic* antimicrobial activity against CRKP, reducing the minimum inhibitory concentrations (MICs) of both drugs, suggesting improved efficacy at lower doses. This combination targets difficult-to-treat bacterial infections, especially those resistant to carbapenems[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AS-101 + zidovudine.